What is Luminopia?
Founded in 2016, Luminopia is at the forefront of developing digital therapeutics designed to address significant neuro-visual disorders. The company's mission is to create rigorously evaluated, FDA-approvable digital treatments that are also engaging for patients. As an Innovation Partner of Boston Children's Hospital, Luminopia is advancing its lead product, Luminopia One, which aims to enhance vision in children suffering from amblyopia, a leading cause of visual impairment in pediatric populations. This strategic focus positions Luminopia as a key player in the intersection of healthcare technology and patient care.
How much funding has Luminopia raised?
Luminopia has raised a total of $26.5M across 2 funding rounds:
Angel/Seed
$10.5M
Series A
$16M
Angel/Seed (2022): $10.5M with participation from The Vertical Group, ShangBay Capital, Sony Innovation Fund, and SSI Strategy
Series A (2023): $16M led by U.S. Venture Partners, ShangBay Capital, and Broadfin Capital
Key Investors in Luminopia
U.S. Venture Partners
U.S. Venture Partners (USVP) is a prominent Silicon Valley venture capital firm dedicated to collaborating with entrepreneurs to develop transformative companies, specializing in early-stage investments across cybersecurity, enterprise software, consumer products, and healthcare.
ShangBay Capital
ShangBay Capital is a venture capital company specializing in medical devices, biotechnology, and healthcare, with a focus on seed and early-stage investments. Founded in 2015, the firm is headquartered in Palo Alto, California.
Broadfin Capital
Broadfin Capital is a healthcare-focused investment firm founded in 2005, specializing in unique investment opportunities within the healthcare sector and offering comprehensive investment strategies.
What's next for Luminopia?
The recent major strategic investment signifies a pivotal moment for Luminopia, likely enabling the company to accelerate its product development pipeline, expand its clinical trial initiatives, and scale its commercialization efforts. This capital infusion, coupled with the company's established partnerships and focus on FDA-approved digital therapeutics, suggests a trajectory towards market leadership in treating neuro-visual disorders. Luminopia's commitment to rigorous evaluation and patient engagement is expected to drive further growth and solidify its position in the digital health landscape.
See full Luminopia company page
